IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Blair William & Co. IL

Blair William & Co. IL lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 8.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,072 shares of the medical research company’s stock after purchasing an additional 328 shares during the period. Blair William & Co. IL’s holdings in IQVIA were worth $861,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in IQV. 9258 Wealth Management LLC increased its position in shares of IQVIA by 35.9% during the fourth quarter. 9258 Wealth Management LLC now owns 2,915 shares of the medical research company’s stock worth $674,000 after purchasing an additional 770 shares in the last quarter. Quest Partners LLC acquired a new position in IQVIA in the 4th quarter valued at about $182,000. US Bancorp DE increased its position in IQVIA by 0.6% in the 4th quarter. US Bancorp DE now owns 18,533 shares of the medical research company’s stock valued at $4,288,000 after acquiring an additional 117 shares during the period. Nomura Asset Management Co. Ltd. increased its position in IQVIA by 2.0% in the 4th quarter. Nomura Asset Management Co. Ltd. now owns 48,057 shares of the medical research company’s stock valued at $11,119,000 after acquiring an additional 954 shares during the period. Finally, Steward Partners Investment Advisory LLC increased its position in IQVIA by 0.7% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 27,547 shares of the medical research company’s stock valued at $6,374,000 after acquiring an additional 182 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the topic of several recent research reports. Robert W. Baird boosted their price target on IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research report on Friday, September 20th. Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and dropped their price target for the company from $266.00 to $242.00 in a research report on Wednesday, July 24th. Argus upgraded IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Barclays boosted their target price on IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 23rd. Finally, StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Thursday, September 5th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $267.00.

IQVIA Price Performance

IQV stock opened at $239.57 on Wednesday. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The stock’s 50 day moving average price is $241.03 and its 200 day moving average price is $233.69. The firm has a market cap of $43.65 billion, a P/E ratio of 32.73, a PEG ratio of 2.25 and a beta of 1.49.

IQVIA (NYSE:IQV) last posted its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. During the same quarter in the prior year, the company earned $2.22 EPS. IQVIA’s revenue was up 2.3% on a year-over-year basis. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.60% of the stock is owned by corporate insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.